5月7日 - ** 癌症疗法开发商Theriva Biologics TOVX.A股价盘前上涨80%至2.45美元
** 该公司称 (link)，在一项中期试验中，其实验性抗癌药物zabilugene almadenorepvec与化疗一起使用时，达到了提高总生存期和降低疾病进展风险的主要目标。
** 与只接受化疗的患者相比，接受该药物和标准化疗的患者的生存期更长，为 10.8 个月，而只接受化疗的患者的生存期为 8.6 个月 - TOVX
** 这种药物正在接受一线治疗转移性胰腺导管腺癌的试验--这是一种始于胰腺导管并已扩散到身体其他部位的癌症。
** 公司称已对 140 多名患者进行了药物测试，患者耐受性良好
** 截至上一交易日收盘，股价累计下跌 22.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.